Stories
Neuland Labs Sees Record RFPs as Drugmakers Diversify Beyond China
C
CNBC TV18•23-09-2026, 17:45
Neuland Labs Sees Record RFPs as Drugmakers Diversify Beyond China
- •Neuland Laboratories received a record number of Requests for Proposal (RFPs) in three months, driven by global drugmakers diversifying supply chains away from China.
- •CEO Saharsh Davuluri noted that despite existing peptide capacity in China, innovators are actively seeking alternatives in India, Europe, and other regions.
- •Neuland recently launched operations at its new peptide facility in Hyderabad to meet growing demand.
- •The company is strategically pursuing acquisitions in the CDMO space, particularly in the US, to build capabilities and strengthen its presence closer to customers.
- •This trend of diversifying supply chains extends to the broader Indian Contract Development and Manufacturing Organization (CDMO) sector, with global innovators exploring various capabilities across domestic peers.
Key Questions Answered
Neuland Laboratories recorded its highest number of Requests for Proposal (RFPs) over a three-month period as global pharmaceutical innovators actively look to diversify their supply chains and reduce reliance on China.
Neuland Laboratories is looking to pursue strategic capability acquisitions rather than large capacity acquisitions, with the goal of building a stronger presence closer to customers in the Western Hemisphere, particularly the United States.
Neuland Laboratories reported a net profit of ₹148 crore for the quarter ended June 30, 2026, compared to ₹14 crore in the same period last year, while operating revenue more than doubled to ₹641.5 crore.
